Merck's KEYTRUDA ® (pembrolizumab) Approved in Japan for three additional first-line indications around RCC and chronic or remote metastatic head and neck cancer

Merck’s KEYTRUDA ® (pembrolizumab) Approved in Japan for three additional first-line indications around RCC and chronic or remote metastatic head and neck cancer

KENILWORTH, N.J.-(BUSINESS WIRE)- Merck, branded as MSD outside the United States and Canada, today announced that for the following additional uses in Japan, KEYTRUDA, Merck’s anti-PD-1 medication, received new approvals from the Japan Pharmaceutical and Medical Devices Agency for advanced…

Japan Clinical Research Software Market

Japan Clinical Research Software Market 2019-2025 | Oracle Corporation (US), Medidata Solutions, PAREXEL International Corporation. (US), Bioclinica. (US), Bio-Optronics, Inc. (US), and IBM (US)

Pharmaceutical firms use clinical test management systems to manage clinical trials as a part of their pharmaceutical and biotechnology analysis activities. Medical analysis institutes and research centers managed by hospitals can also use clinical test management code. These systems facilitate…